tenascin XA (pseudogene)Genealiases: D6S103E · HXBL · TNX · XA
Q-omics provides the consensus-scored TNXA profile across patient tissues and cancer cell-line models. TNXA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TNXA is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TNXA RNA expression shows 11,564 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KIRC, and KIRP as cancer lineages where TNXA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNXA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNXA survival associations across molecular data types. TNXA RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNXA RNA expression–survival associations across cancer types. High TNXA expression shows unfavorable associations in LUAD, KICH, KIRC, CHOL and ACC, but favorable associations in KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TNXA RNA expression.
This table summarizes TNXA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TNXA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNXA shows lower tumor expression in BLCA, LUSC, KICH and LUAD and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TNXA RNA expression in tumor versus normal tissue (log2 FC = +0.447, t-test p < 0.001).
This table shows molecular features associated with TNXA in patient tissues and cancer cell lines. In patient samples, TNXA shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
